Since adenosine exerts an immunosuppressive activity, as observed in the bone marrow niche in multiple myeloma, targeting CD38 with daratumumab may also boost host-antitumor immune response, although these preliminary observations need to be confirmed [66,67]. The gene discussed is CD38; the disease is plasma cell myeloma.